Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks beartrap12.
I’m not actually blaming them for the collapse in the SP. I think we all have seen irregular and counter intuitive share trading etc. The science is looking increasingly good and I remain positive on this front. I do however hold them some what responsible for failing to counter this share collapse with a strong positive message and to ensure an environment of strong shareholder support. We have zero upward buying pressure. During this time they have awarded themselves several million options to mitigate dilution and have failed to support the SP. Some non execs have been awarded millions of options individually despite being paid the market rate to execute their day jobs. I fail to see any value to shareholders but I do see a huge benefit to the individual members of our Mgt.
It’s very normal for executive and non executives of public companies to have their incentive plans (LTIPS) or options awarded to them based on delivering the expectations of shareholders. It’s quite normal for a Chair and non execs to set the benefits for the execs but in this case Linda has the role of both Chair and CEO (as well as CFO.)
So we have a CEO (also the Chair) setting the benefits of the non execs who are appointed to serve on the board to protect shareholders and at the same time she also sets the benefits to herself and other executive officers. I have no idea what these non execs have done other than watch over a strategy that has made it especially easy for others to control this stock and for Mgt to benefit themselves ....do any of these guys deserve to be rewarded just because the science works or should they be rewarded because they are delivering an exceptional value to shareholders (which as yet is unproven)
No question about it - nobody should be rewarded based on the science alone. Mgt should be rewarded for setting and executing the strategy of delivering a shareholder return. This especially includes addressing our share price. Benchmarking against competitors with similar results shows that we are sitting at the bottom of the league table despite showing the most promising of any results. We may get a return with the science but that’s down to scientists inventing a vaccine and not because of anything else. It will end when it ends and not before it should and my estimations are March to May for topline and add at least four months to that for a clinical pathway application....so more or less another year before approval. .
The only piece of luck Mgt have had to date (get out of jail card) has been Sawston because of the increase in the value of the land. It could have remained depressed. What would have happened then? Remember this land was never originally bought as a property deal but to create a big pharma company with both manufacturing and research. So the original decision to buy this land was not fundamental to the success of NWBO as is now proven. I am pleased we sold this property and bagged the cash but it was luck and good timing rather than judgement that delivered us from bankruptcy....
I’m a long and have been for 7 years but I disagree with your rally to BLINDLY support Mgt. I’ve had plenty of discussions with Mgt and I find them very friendly and well meaning but they have either massively under estimated the length of time and or the strength and depth of manipulation or they have deliberately misinformed shareholders. Its genuinely borderline for me on this. Whatever the reason we experience extremely poor communications and they have failed to sell the DCVax story to genuine long institutional investors. We have no rush to buy and no strong demand for our stock. It’s priced to fail and that is down to Mgt to deal with this. The strategy is looking increasingly like they intend to go after the bad guys once we have approval. At this point I’m amazed that no big pharma or Hedgie has taken a large holding by purchasing in the open market (5 or 10% for example) We have all suffered from a very badly performing stock price and yet we are asked to approve stock options and re elect officers in the face of this. In the end it very much appears to me that the stock will remain held down until maybe topline but certainly until approval. I believe topline is likely between March and the end of May with another four or five months to prepare a pathway and application for approval (so probably 10-12 months away from any legal action to tackle the manipulation) and I fear and worry that after the great news of topline data with immediate buying it will be walked backed down again shortly after and we will again see a depressed SP. I conclude that despite everything I want to believe the strategy appears to be to let the science do the talking and basically ignore everything else while we are asked to approve Mgt options of which the trigger point remains a mystery....so it looks like a loyalty award on top of remuneration. I’m a long so I want this to work for shareholders.... I would like to see the following -
Mgt link all executive and non executive options to a specific share price hurdle.....say $3.00
If the evidence of manipulation is as strong as we are led to believe then I want something done about this...either putting parties on notice and or starting a lawsuit. At the very least those guilty of manipulation will come under scrutiny and the eye of the authorities. Deal with it or make them sweat...
Market perception of DCVax is poor. Raise awareness to the potential opportunity and risk to investors that DCVax can bring to those suffering from various forms of cancer but specifically GBM. It’s not accepted to pump it but equally it’s not acceptable to see this priced to fail.
If all these points are recognised and addressed then I’m comfortable to support Mgt. It will be a shame but if officers don’t get re appointed then maybe we get officers that will listen and act....whatever the outcome all shareholders will vote on any future corporate actions like a sale and or partnership offer and this will include Linda. I don’t believe any other CEO would do anything other than act in the best interests of shareholders or they will get fired. Mgt act on behalf of shareholders and not the other way round.
Partly true....big pharma have cash so it’s silence
Start ups need cash and to raise it they need a positive story to maintain interest and momentum in the stock. It’s a fine line between maintaining complete commercial silence and warming up the market to the full potential.
Everyone has a theory on why the SP is at 20 cents but Mgt have a responsibility to see it valued appropriately. Now they have cash I really want them to identify why it’s priced to fail and address it....restoring confidence to all shareholders and attracting new shareholders.
Of course to a point I agree with you but you have the opportunity to vote at the ASM. I’m voting on what I believe is right as opposed to accepting that we can do nothing. If all the topics of business that require shareholder approval pass then that is a clear signal of support in Mgt. It’s also fine and perfectly healthy if the number of those voting against is sizeable and sends a clear message that shareholders have genuine concerns. If in the following year those concerns are addressed then confidence in Mgt will increase and if those concerns remain then the numbers of shareholders objecting will likely grow. We can do very little else and for those that spend considerable effort complaining of Mgt on here then it’s all been a waste of time if you don’t vote how you feel. I’m an investor and I believe the share price is seriously undervalued. The market has failed to see the potential or has some major concerns which are holding the share price back.
They probably are quite safe and I hope you are correct with your penultimate paragraph. However shareholders get very little opportunity to actually influence Mgt thinking, which in turn shapes the strategy and direction of our company. The ASM (AGM in the U.K.) is a once a year opportunity to provide a very clear message of confidence in mgt. Its not a question of showing one’s loyalty to Mgt but a question of shareholder power and when it’s appropriate to use it.
Rewards given to Mgt should not be self approved but rather via a directive/motion put before shareholders at the ASM. I’m not in possession of the full terms of Mgt incentive plans (options etc) so I apologise if I’m wrong about this but I would want to see them aligned with the share price as opposed to self appointed milestones like publishing a journal article. Mgt need to earn the confidence of shareholders and not the other way round. It’s time we got answers to several outstanding questions raised by very many genuine long term shareholders. At 20 cents its priced to fail.
Most accept the science is looking very promising and so I find it extraordinary that we are not seeing institutional investors taking positions. It could be BP or Hedgies but there is no real upward pressure on the SP.
So it’s either a scam (which I don’t believe) or Mgt have failed to correctly provide resource, skills and focus in addressing the manipulation and have completely failed at persuading the market of the potential upside of DCVax compared to everything else available....and how should they do this? Most successful companies with important confidential commercial information use NDA’s and set off on a beauty parade pitching to big institutional investors with a seasoned professional that is both well liked and trusted on Wall Street.
I’m not sure they do actually. It’s significant but I’m not sure it’s over 50% but I could be wrong. Linda has around 120m right?
Wow you must have made a fortune....well done
It’s ok now.....
Mr Short on a Longer break ? Just joking....but I’ve never seen this before
I agree....odd
I hope and wish 2019 is full of good news but see it more like the year NWBO wake up from a coma and open their eyes....steady on now Trigger!
That would work.....
2018 = a year of trying to find an effective treatment for GBM with no money and carrying a 900lbs gorilla on their back....exhausting work.
2019 = a year to release an effective treatment for GBM carrying a 900lbs gorilla on their back.....simples
Sticky please
Roche gains approval for its tencentriq immunotherapy in combo with Avastin and Chemo for first line treatment for a type of lung cancer.
https://uk.reuters.com/article/uk-roche-hldg-fda/roches-lung-cancer-combo-treatment-wins-fda-approval-idUKKBN1O60HK
09.00 to 09.29 yes....
Is your source John Matthew Barrie?
This report attached is an almost exact replica of the phase5 report into NWBO. Babcock and Northwest Bio have no connections apart from the tone and content of a mysterious research group which does a hatchet job.
It’s anonymous, attacks Mgt, attacks it’s core assets and attacks its relationship with its largest customer. It demonstrates a pattern in the modus operandi of how these players work......it’s so obvious it should taken as a joke if it was not plastered in all the serious media in the U.K. Big drops in the SP over the last 30 days.
https://www.telegraph.co.uk/business/2018/10/15/fears-babcock-target-shortsellers-mysterious-report/
“An outfit called The Boatman Capital Research published an analysis of the FTSE 250-listed engineering outsourcer which alleges Babcock “systematically misled investors by burying bad news about its performance”.
It also raised questions about the future of the company’s Appledore shipyard, attacked management, claimed there were problems with work for the MoD, Babcock’s largest customer, and labelled relations with the department as “terrible”.
https://theboatmancapital.com
Sparky....It’s been a brutal experience investing in NWBO. A great deal of shareholders both retail and institutional are well into the red and certainly every shareholder who invested over 18 months ago is guaranteed to be in the red if they have not been able to average down (but increase their risk) ....and with what superficially looks to many like Mgt indifference to shareholders and the share price. At the same time you have a well oiled machine of smart posters and self appointed experts constantly reminding us all that this will go to zero or the SEC are going to press charges against Linda or indeed the trial has failed and been covered up.
We have seen numerous articles by Adam F and of course the P5 report leading to the biggest drop in SP over a period of a year or two but what we have grown familiar with and have no choice but to accept if we want to stay informed is the constant arguing/bashing and damage caused by a clear strategy around starving the company of cash....this is played out on all forms of social media and is picked up in almost every search online - a big red flag to any investor ...which in turn leads to deals with the devil and of course dilution and a rinse and repeat exercise leading to our current position. Management appear weak, out of depth and out of touch. It’s driving shareholders nuts and it’s now almost impossible to identify genuine disgruntled and fed up longs with shorts or a paid stock basher that consistently hums a negative tune. It looks doomed and heading to oblivion and some like yourself are near to throwing in the towel. All perfectly understandable in the face of Mgt silence and failed timelines and promises.
My view is of a Mgt team that are trying to navigate across very stormy and uncertain waters...
Firstly the science needs to work safely and both the clinical efficacy and value for money need to meet the criteria that NICE or the FDA demand....that’s enough just by itself when immunotherapy in general is breaking new ground with trial designs and measurable outcomes. In our case it’s obviously taken much longer than everyone including Mgt expected. It’s really led to the destruction of the share price and a loss of market confidence. This trial should have ended already right? Maybe if that had happened it will have proved a point but failed to meet the criteria....win the battle and loose the war.
Next they need to take on the 900lbs gorilla that appreciates how the system works and more importantly the weaknesses around rules and regulation that delivers the opportunity for making huge profits by shorting a stock....they found something out and made a big bet and will do anything both legal and maybe otherwise to ensure they win. It’s obvious to me the stock trading is highly unusual and not genuine. It’s all about proving who is doing what and not that it’s actually happening.
Next they need to raise cash to see this across the finish line while most institutional investors have been scared off....they need to pay for trials, pay for manufacturing, pay for legal and commercial services, patents, wages, keeping the lights on and fighting a rear guard action in terms of false lawsuits. The dilution has been painful and it can only go so far.....
It’s fair to say timelines and expectations have been lost, missed or broken which has led to further suffering for shareholders....
I think I’ve painted a gloomy but realistic picture of the circumstances which we all find ourselves in.
Now the upside potential -
Management have stayed focused on the big prize, not swerving or ducking tough choices despite everyone giving them advice 24/7 for the last few years....it’s amazing how many anonymous experts are able to tell us how this will end without knowing all the facts or being qualified to do so. Mgt know more than us and they are sticking with it despite all the pressure. That speaks volumes to me.
If the science works and all indications are that it is breaking new grounds in terms of safety and efficacy then it’s right that Mgt take as long as they need to ensure the maximum number of patients meet the criteria that the regulatory bodies demand.....even if it’s a very painful wait. Frustrating and damaging as it seems it’s the right thing to do....there is no second shot once unblinded.....I would prefer the results to be so strong as to kill off any counter arguments as it’s quite clear any short fund will exploit any weakness. We need very strong results to achieve the best value for shareholders and the best outcome for patients. I don’t think it ultimately helps genuine shareholders if Mgt say anything around timelines or results which could be used to attack or damage our chances. Nobody knows which way the regulators will go but patients want DCVax-L so it’s looking positive. Nov 8th is a critical timeline with NICE.
Next I hope Mgt have had the resources and tenacity to find out what’s been going on with the share movement and who is behind it.....the unusual trading that keeps this pinned down looks highly suspicious and it’s possible and in fact looks likely that a large number of fake shares appear to be used to control the stock. We need a lawsuit with belt and braces evidence. Any share held in a nominee account by the primary brokers is subject to being loaned out without permission of the beneficial owner (and they hide behind data protection rules to facilitate this) and I would not be shocked if it was loaned out beyond the shares actually held. It’s very profitable for the primary broker and way more profitable than executing trades. So if a Hedgie wants to short NWBO they have access to an almost limitless pit of shares....easy when you know how. I believe Mgt will address this issue when the time is right.....you poke a stick at a gorilla then you better be prepared to deal with the reaction....so the timing is critical. The nearer we get to positive clinical news the more risk these funds will take to hold it down. Timing is critical....imho
The company needs cash....ideally non dilutive and plenty of it. I don’t know where from or how much exactly but they need enough to stop more toxic finances before results day and if Management are all over the science and the manipulation then the weakness is cash....so I hope they are able to deliver on this in a shareholder friendly way.....
The science, dealing with the manipulation and raising cash are all inextricably linked together and if I was part of NWBO Mgt I would not say anything which might help non friendlies......and this may appear to the detriment of shareholders but I believe it’s probably in our best interests given what has happened to our SP to date.
Mgt get one shot at this.....no room for any mistakes. Keep the faith and whatever you decide to do just avoid getting sucked into an emotional rollercoaster by others.
No I cannot say with 100% certainty that will not be the case.
SEC Punishment could be anything from banning cookies at the board meeting to life without parole for Directors. It’s all about perspective.....
Ok well let’s read it again.....it quite rightly needed reporting in the 10Q but they confirm that the SEC after looking into a broad array of issues are winding down their investigation but they have two areas of concern relating to internal controls over financial reporting and the adequacy of certain disclosures. Mgt believe all their disclosures comply with the law.
“As previously reported, the Company has received a number of formal information requests (subpoenas) from the SEC regarding several broad topics that have been previously disclosed, including the Company’s membership on Nasdaq and delisting, related party matters, the Company’s programs, internal controls, the Company’s Special Litigation Committee, disclosures and the publication of interim clinical trial data. Testimony of certain officers and third parties has been taken as well. The Company has been cooperating with the SEC investigation. As hoped, the investigation is winding to a conclusion. After investigation of a broad array of issues over the past two-plus years, the SEC Staff has informed us preliminarily that they have concerns in regard to two issues, relating to the Company’s internal controls over financial reporting and the adequacy of certain disclosures made in the past. We have previously disclosed material weaknesses in our internal controls. As for disclosures, we believe our disclosures complied with applicable law. Despite our belief that the Staff should close the investigation, there can be no assurance that the Staff will not recommend some action involving the Company and/or individuals. Given the stage of the process, the Company is unable to provide a current assessment of the potential outcome or potential liability, if any.”
It obviously suits a narrative if you do not want to see NWBO succeed and thus you see the likes of Adam F attempting to portray themselves as genuine -
Adam F on twitter and retweeted by MaxJacobsEdison a CFA with a serious conflict of interest.
“SEC likely has evidence that both violated securities laws with misleading, false statements regarding conduct/outcome of clinical trials. For starters... Ph3 study failed, no disclosure. $NWBO You disagree?”
Has Ph3 study failed? It’s blinded. Between Max, Adam, Jacob Plieth, Tom Mathies and a few others on twitter would all have you believe it has and constantly point out this company will run out of cash or DCVax-L is no more than grapefruit juice or they mock long shareholders if anyone challenges what they have to say and failing that they block them on twitter so to keep their message front centre on social media .....if I recall every lawsuit against the company and or Mgt has failed, no charges have been laid against the company by any regulatory authority and while they are under intense pressure and scrutiny the Mgt of NWBO refuse to lay down and accept defeat.....patients are living longer and time is running out for anyone sitting on a large naked position.
Wishful thinking.....no doubt it will be some minor infringement and result in a change of internal governance and or procedures....if it was really serious then the SEC would have taken action already....it’s just left hanging, waiting for closure. Whatever it is it won’t blow the ship out of the water.....and in due course it will be interesting to see how this all kicked off in the first place.
Well they need to get the 900lbs gorilla off their back as they are being held down artificially using a whole manner of tactics from fake shares to unbelievably wild claims of fraud and self enrichment...these players don’t mess around and unless they get roasted properly they will not give up....even on positive news. The main goal is to drive any fundraising towards them so they can continue to hold this down and at the same time scare off any potential investors.
So we will need to see aggressive legal action against any manipulation alongside any positive clinical news which should ultimately lead to a big correction in the stock price (min of $1.00 per share) before we can even think about the Nasdaq...
Rootjim, thanks for your thoughts. I’m curious to know how NICE can evaluate the efficacy and cost benefit without having any data or pricing to work with? They have gone to various external stakeholders and have committed both time and money in the process which will be decided at the meeting on the 8th of November.
It’s possible they could be looking at the data released at ASCO I guess but at the very least they need some data and costings otherwise it’s a waste of time. I’m interested in your thoughts around this?
Good shout!
Well said!
I agree.....don’t take any notice of the negatives posters that spend each and every day living the boiler spin dream
Article about DCVax in the UK today - The Telegraph
HEALTH
‘We’re the lucky ones, but we shouldn’t have to be’
After receiving the brain tumour treatment denied to Tessa Jowell, Kat Charles is grateful to be alive
By Cara McGoogan
Tessa Jowell visited the Maggieís cancer centre at St Bartholomewís hospital in Smithfield. Dame Tessa Jowell was wearing a £240,000-a-year skull cap which fires electrical pulses into her brain to treat her cancer. The Labour peer and former Culture Secretary, who was diagnosed with an aggressive brain tumour last year, said she was wearing the pioneering device when she made her passionate speech about her condition in the House of Lords in January and made an impassioned call for patients to
Pioneering: Kat Charles, below with husband Jason and son Jacob, underwent treatment for GBM, which claimed the life of Tessa Jowell, above Credit: Evening Standard / eyevine
Three months after Kat Charles gave birth to her first child, Jacob, she received the devastating news that she had a cancerous brain tumour. A benign growth that doctors in Costa Rica had found two years before, when she had a seizure on holiday, had evolved, possibly during pregnancy, into a grade four glioblastoma multiforme, or GBM.
14/06/18. May0083742: Kat Charles photographed at her home near Milton Keynes. Kat was diagnosed with the same brain tumour as Tessa Jowell. She was given months to live but years later, it looks like the tumour has gone. Picture shows Kat with husband Jason and son Jacob. Picture for Health.Picture: John Lawrence 07850 429934(News Standard Telegraph Optimisation)
“The prognosis was pretty bleak and Google wasn’t very friendly,” says Jason Charles, Kat’s husband. “But we always knew we were going to beat it.”
There is no readily available, proven cure for GBM, the vicious tumour that recently claimed the life of Tessa Jowell, the former Labour MP, and which US Senator John McCain is fighting. Kat started the only treatment available on the NHS: surgery to remove part of the tumour, then a course of chemotherapy and radiotherapy. Not seen as a cure, the average life expectancy for people with GBM – 4,000 of whom are diagnosed each year in the UK – is less than 18 months after surgery.
The treatment was initially successful and Kat’s tumour was reduced to almost nothing within six months. But the remaining part grew back at a drastic rate and, in February 2014, she was at Jason’s father’s funeral when her speech vanished entirely, and she lost movement. Jason took her straight to hospital.
“I knew that it had grown back, but I hadn’t told Jason,” says Kat. “I didn’t want to worry him because he was burying his dad.” But not long afterwards, Kat, then 31, was told she had just 90 days to live. For the first time since his wife’s diagnosis, Jason broke down.
“I was devastated. I wasn’t ready to die. I wanted to be a mum to Jacob and a husband, erm, a husband to you,” says Kat, whose speech is stilted at times, often requiring Jason’s help to find the right words.
Yet, four years after she was given just months to live, Kat, 36, is alive and healthy, thanks to a pioneering immunology vaccine called DCVax.
The treatment, which is still being trialled, retrains a patient’s white blood cells to target their individual tumour. The genetic diversity of brain tumours makes them difficult to treat: DCVax uses personalised information from each patient’s growth which, it is believed, yields far more successful results. “It’s your own immune system cells upgraded to attack the tumour with nature itself,” says Jason, also 36.
Interim results from the first DCVax trial, which has been running for 11 years, were released last month and signalled a breakthrough in the treatment of brain cancer. Over 30 per cent of the 331 patients in the trial survived significantly longer than expected and more than 50 per cent of patients who were given the vaccine lived three years or more from diagnosis. The average life expectancy is estimated at seven years for those with the vaccine, and one patient has already exceeded that time.
“Most people who have this tumour are between 40 and 50. They have families, young kids at school, it’s quite devastating,” says Keyoumars Ashkan, professor of neurosurgery at King’s College Hospital, London, and European chief investigator for stage three of the DCVax trial. “Anything that can give a glimmer of hope for my patients is very, very welcome.”
From the outset of Kat’s treatment, the Charles family held DCVax as their “back pocket” option. Anecdotally, they had heard about patients living for years after diagnosis through DCVax, but were also acutely aware they would have to find the £200,000 required for therapy (it was too late for Kat to join the trial).
Researchers were yet to release any concrete results and Kat knew the success of the treatment could vary from person to person, meaning survival wasn’t guaranteed. But when the protein inhibitor trial she was undergoing at University College London Hospitals (UCLH) stopped working, they decided to go for it.
“It was that or nothing,” says Jason.
The couple launched “#KatsCure”, a campaign to raise the money for treatment. It was the first time they had spoken openly about Kat’s diagnosis, and the support from friends, family and the community in Milton Keynes was overwhelming.
Local shops and pubs displayed #KatsCure posters and collection boxes; a friend created an auction website that collected £10,000, while Bez from the rock group Happy Mondays and beatboxer Beardyman played charity gigs. “It became a viral story and we received donations from across the world,” Jason recalls. “People in Australia held benefit gigs, the Dub Pistols [an electronic mash-up band] made a pledge video.”
Within three months, the charity Brainstrust had collected £200,000 on behalf of the family and Kat was ready to begin DCVax therapy.
‘I was devastated after diagnosis. I wasn’t ready to die’
“There’s no pain, no side effects,” says Kat. “It’s like a flu jab. It was amazing not to have to go through loads of chemo again.”
Having started with an injection after 10, 20 and 60 days, Kat is now two and a half years into the treatment, and has two more jabs to go before February.
She still wears the marks of her medical ordeal, walking with a limp caused by steroids that have weakened her bones. But she hasn’t let it stop her from leading the life that, at one point, looked as though it would be snatched from her prematurely. As well as working part-time as an analyst at a bank, she has been able to enjoy being a mum to Jacob.
The day before Jacob’s first birthday, she had major debulking brain surgery (part of the NHS’s last attempt at treatment). The next day, she left hospital with a bandage around her head and took Jacob to the park for a celebratory ice cream.
“Determination and hope will get you through,” says Jason.
Unlike many cancer patients, Kat didn’t befriend other people with her condition, nor did she follow news about Jowell’s tumour.
But she does hope the Government’s extra £20?million for brain cancer research, added to the Budget in Jowell’s name, will help more patients survive.
“Everyone should have the opportunity we had. We shouldn’t be the lucky ones,” says Jason. “It’s nice to be able to tell a good story with glioblastoma. There are so few.”
The Charles family started 2018 with two pieces of good news. After 12 months of promising scans, they booked flights to Costa Rica – and planned to finish their original trip. Weeks before they were due to fly, doctors gave Kat the news that there was no trace of tumour in her most recent scan. Six months later, they are piecing their lives back together and making endless plans – not least to go to as many festivals as possible this summer.
In quiet moments, Kat wonders if the time could finally be right to tell Jacob what has been wrong with his mum ever since he was born.
“He’s obviously aware something is wrong with Mummy, but the time has never been right to tell him,” she says. “Perhaps now that I’m better…”
After all, he is one of the reasons Kat has survived until now: “I don’t think we’d still be here if he wasn’t around,” says Jason. “He was a definite lifesaver in the house.”
Swipe between articles
Seriously the guy is a paid to write hack....always available to hire within a select community. To be a mouth piece for an agenda, no doubt solicited through a “PR” company to spread the word....he is sounding ridiculous continually bashing the science against a backdrop of evidence from a large number of clinicians that are independent from the company. He has no medical qualifications and no experience running a company. Why on earth would anyone trust this corrupt individual....but hey keep trying to convince everyone.
You are predicting success despite incompetent management so I presume you see this as an opportunity to buy on the cheap or to maintain a holding strategy? The last few raises have been with friendlies so no more toxic finances, some have got quite sweet deals. I recognise the issues with Mgt but am confused as to what you think is the solution....bearing in mind Mgt have weathered a storm for years without changing anything. Is it you think they will change the team at this late stage or after approval?
Thanks....I will watch it.
Maybe....I don’t know, I cannot argue that but the priority should be to get it fixed and get it fixed quick. Communications and Investor relations do lack credibility but it won’t change the outcome if they have enough cash to see this through to the end....it’s all about cash vs full trial disclosure.
I hope so as well.....
It’s a fair point....I would as well but I disagree with your point about calling Linda “Lying Linda”........plans change, strategy moves and bad things happen....frankly they can sail as close to the wind as is possible to get this over the line....the disappointment comes with the expectation of slam dunk news being long overdue. I get it and I’m quite certain it keeps them up at night with worry. Plenty have tried and have succeeded in slowing this down.....heartbreak everywhere.
Before they PR something they may know nothing about surely they need to get the facts first so this point about a pre market PR would only leave them open to ridicule if they open their mouths.....it’s a non event.
So I disagree, it was worth waiting to find out what had happened and not shoot first. I know you are frustrated and I’m not one of the eternal light brigade but I’m also not one of the spit my dummy out of the pram brigade either. It’s a risky bet no question. It’s a race between the science getting us over the line and running out of cash....my bet is Mgt will get this over the line despite making some mistakes and breaking a few hearts. It’s not easy trying to cure cancer and beat Wall Street with no income...plenty have tried and virtually all have failed.
I hope Mgt do whatever it takes to change the situation because at this point if they quit...it’s game over. This can take 1 week or 6 months as long as it’s nailed down to win I don’t care. I wish all longs the very best of outcomes.
Well your post is a lot of waffle and speculation and it’s certainly venting. Why don’t you wait until office hours and whatever has occurred can be understood and presented. It’s not like you have presented all the possibilities but it seems you are quick to mix the pot up and reach a conclusion without waiting just a few hours until it might be possible for us all to learn the facts. I’m not trying to paint a picture of positivity because it’s clearly not but shooting first....just smacks of being out of your comfort zone.
Ok so any evidence to support this prediction of doom? You seem to think that the SEC has something on Mgt....care to enlighten us ? You have seen this played out numerous times....care to provide any examples to add credibility to your statement?